Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

20,689 21,632

Deferred revenue 57,027 61,349

Deferred gain 7,323 8,680

Other long-term liabilities 11,159 5,911

Total liabilities 459,720 510,664

Commitments and contingencies

Stockholders' equity:

Preferred stock - -

Common stock 9 9

Capital in excess of par value 1,309,973 1,302,541

Accumulated other comprehensive income (478) 1,643

Accumulated deficit (1,200,872) (1,089,754)

Total stockholders' equity 108,632 214,439

Total liabilities and stockholders' equity $568,352 $725,103

(1) The consolidated balance sheet at December 31, 2007 has been derived

from the audited financial statements at that date but does not

include all of the information and notes required by generally

accepted accounting principles in the United States for complete

financial statements. Certain 2007 amounts have been reclassified

between line items to conform with the 2008 presentation.

NEKTAR THERAPEUTICS

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, except per share information)

(unaudited)

Nine Months Ended

September 30,

2008 2007

Cash flows used in operating activities:

Net loss $(1
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... The body parts industry, which suffered two recent scams, is ... United States . According to official reports, the billion-dollar industry ... call for a doubling of FDA inspections. ,From ... of inspections, and accordingly, the 153 searches, have uncovered no ...
... even after they stop smoking, says a new study, ... smoking ceases . ,The new finding is the ... with bronchial inflammation, it will continue even after they ... team of researchers in respiratory medicine including New Zealand ...
... international team of researchers has found evidence that people ... sleep disorder called restless legs syndrome (RLS) are ... ,RLS is a common and debilitating sleep disorder that ... people worldwide. It produces an intense, often irresistible urge ...
... even at the cost of lives, are turning out to ... are far less likely than whites to get specialized ... leave them more vulnerable to future fatal attacks. ... American Medical Association, tracked 1.2 million Medicare patients at least ...
... A US court has authorised Israeli generic medicines group Teva ... patent lawsuit by Novartis, the Swiss pharmaceutical group said on ... rejected on Monday a request from Novartis to stop Teva ... pending a trial in the case, the Swiss group said ...
... down on Madhya Pradesh Tuesday, taking temperatures to more than 46 ... heat wave claimed six more lives taking the toll to ... saying the hot weather would persist for the next two days. ... Morena and Damoh. ,The mercury soared to more ...
Cached Medicine News:Health News:Body Parts Industry Of U.S Under Investigation 2Health News:Boffins Find Link Between Common Sleep Disorder and Hypertension 2Health News:Racial Discrimination Takes The Nobility Out Of Doctoring 2
(Date:1/23/2015)... Jan. 23, 2015  Pete Rose, baseball,s all-time hits leader, is ... pain reliever Myoflex, Ducere Pharma has announced. "Pete,s ... excited to have him on board with Myoflex," said Ducere ... a legendary player who is known across all generations. The ...
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
(Date:1/23/2015)... Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of ... compound, LB‑100, is being conducted, has been expanded from 1 ... M.D., the founder and President of Lixte, said that, "the ... site. Accrual of patients, however, was slower than projected. The ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Stent with Polyzene(R)-F Surface Treatment Maximizes,Endothelialization; ... Antiplatelet Therapy, WASHINGTON, Oct. 13 ... and Futuristic Therapies" session during the ... sponsored by the Cardiovascular Research Foundation, ...
... Facet Solutions, Inc. today,announced the completion of 6 month ... The results show a 78% reduction in Oswestry Disability,Index ... Scores (VAS) for,symptomatic leg pain. Geoff Pardo, President & ... these early results, which thus far not,only demonstrate significant ...
Cached Medicine Technology:12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4
Inquire...
Inquire...
... HV high-voltage power supply, 100-120 ... increased output of 5,000 V, ... Built-in infrared capability allows for ... and instructions are provided. Dimensions ...
... Form: Granular, free-flowing powder EEO (-m r ): ... 1.5C Remelt Point (1.5%): 88.0 1.5C Gel ... gm/cm 2 Gel Strength (1.5%): greater than ... less than or equal to 7% Turbidity (1.5%): ...
Medicine Products: